Viridian Therapeutics (1S1) Price & Analysis

2 Followers

1S1 Stock Chart & Stats

€20.60

€0.10(0.60%)

At close: Jul 24 4:00 PM EDT

€20.60

€0.10(0.60%)

Day’s Range― - ―

52-Week Range€11.20 - €28.58

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€1.85B

Enterprise Value€1.34B

Total Cash (Recent Filing)€981.53M

Total Debt (Recent Filing)€242.88M

Price to Earnings (P/E)―

Beta>-0.01

Next Earnings

Nov 16, 2026

EPS Estimate

-0.91

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.53

Shares Outstanding113,292,270

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.57

Price to Book (P/B)3.65

Price to Sales (P/S)37.25

P/FCF Ratio-9.53

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€30.44

Price Target Upside47.77% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)-3.46

Revenue Forecast (FY)€19.35M

Bulls Say, Bears Say

Bulls Say

Revenue ExpansionThe substantial revenue increase from the previously very small base indicates meaningful progress in advancing the pipeline and generating economic activity. Sustaining this level can improve development funding capacity and provide a stronger foundation for eventual commercialization.

Balance-sheet FlexibilityA sizable equity base combined with low leverage gives Viridian more financial flexibility than a heavily indebted development biotech. This supports continued investment in clinical programs and reduces the immediate burden of debt service while the pipeline advances.

Funding And Execution ReadinessRecent financing strengthened resources for pipeline development, while full loan repayment reduced future financing obligations. The WuXi manufacturing agreement also supports preparation for potential commercialization, improving execution capacity as programs progress.

Bears Say

Persistent Large LossesThe scale of ongoing losses shows that Viridian remains far from profitability despite higher revenue. Continued heavy operating expenses could consume capital for several periods, making successful clinical development and eventual approval essential to establishing durable earnings.

Severe Cash BurnDeeply negative operating and free cash flow means the business is not yet self-funding and must continue using capital to support operations. Persistent cash burn can require additional financing and may constrain investment choices if development spending remains high.

Dependence On Approvals And FinancingWithout recurring product sales, Viridian depends on clinical progress, regulatory approval, and future commercialization to create operating revenue. Until that transition occurs, financing activity remains important for sustaining programs and exposes the business to ongoing funding requirements.

Viridian Therapeutics News

Viridian Therapeutics price target raised to $38 from $36 at RBC Capital

RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $38 from $36 and keeps an...

23d ago

VRDN

Viridian Therapeutics price target raised to $39 from $38 at Truist

Truist raised the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $38 and keeps a Buy...

2M ago

VRDN

Viridian Therapeutics price target raised to $36 from $35 at RBC Capital

RBC Capital analyst Lisa Walter raised the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $35...

2M ago

VRDN

Joseph Thome Reiterates Buy on Viridian, Citing Strong Early Lumvoa Launch and Long-Term Growth from Elegrobart

TD Cowen analyst Joseph Thome has maintained their bullish stance on VRDN stock, giving a Buy rating yesterday....

2M ago

VRDN

Viridian: Buy Rating Reiterated as Lumvoa Launch Progress Supports Pipeline Outlook; $34 Price Target Unchanged

In a report released today, Serge Belanger from Needham maintained a Buy rating on Viridian Therapeutics, with a...

2M ago

VRDN

Viridian Therapeutics reports EPS ($1.05), consensus ($1.03)

Reports revenue $284,000 vs. $75,000 last year”We are very encouraged by the early indications from our recent launch...

2M ago

VRDN

Viridian Therapeutics sees cash runway through profitability

Cash, cash equivalents, and marketable securities were $981.5 million as of June 30, 2026, compared with $762.2 million...

2M ago

VRDN

“Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market

What to make of the markets today? The biggest story in recent months has been the conflict in...

3M ago

AEIS

VRDN

Viridian Therapeutics price target raised to $43 from $32 at Wedbush

Wedbush analyst Laura Chico raised the firm’s price target on Viridian Therapeutics (VRDN) to $43 from $32 and...

4M ago

VRDN

Viridian Therapeutics price target raised to $38 from $35 at Truist

Truist raised the firm’s price target on Viridian Therapeutics (VRDN) to $38 from $35 and keeps a Buy...

4M ago

VRDN

Viridian Therapeutics price target raised to $35 from $34 at RBC Capital

RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $35 from $34 and keeps an...

4M ago

VRDN

Viridian Therapeutics price target raised to $39 from $35 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $35 and keeps a...

4M ago

VRDN

Viridian Initiated at Buy as Lumivoa FDA Approval Transitions Company to Commercial Stage; $35 Price Target Reiterated

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Viridian Therapeutics, retaining the price target of...

4M ago

VRDN

Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform

As previously reported, Wells Fargo analyst Derek Archila upgraded Viridian Therapeutics (VRDN) to Overweight from Equal Weight with...

4M ago

VRDN

1S1 FAQ

What was Viridian Therapeutics’s price range in the past 12 months?

Viridian Therapeutics lowest stock price was €11.20 and its highest was €28.58 in the past 12 months.

What is Viridian Therapeutics’s market cap?

Viridian Therapeutics’s market cap is €1.85B.

When is Viridian Therapeutics’s upcoming earnings report date?

Viridian Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 32 days.

How were Viridian Therapeutics’s earnings last quarter?

Viridian Therapeutics released its earnings results on Aug 06, 2026. The company reported -€0.937 earnings per share for the quarter, missing the consensus estimate of -€0.924 by -€0.013.

Is Viridian Therapeutics overvalued?

According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viridian Therapeutics pay dividends?

Viridian Therapeutics does not currently pay dividends.

What is Viridian Therapeutics’s EPS estimate?

Viridian Therapeutics’s EPS estimate is -0.91.

How many shares outstanding does Viridian Therapeutics have?

Viridian Therapeutics has 113,292,270 shares outstanding.

What happened to Viridian Therapeutics’s price movement after its last earnings report?

Viridian Therapeutics reported an EPS of -€0.937 in its last earnings report, missing expectations of -€0.924. Following the earnings report the stock price went down -2.222%.

Which hedge fund is a major shareholder of Viridian Therapeutics?

Currently, no hedge funds are holding shares in DE:1S1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Viridian Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-61.35%

Trailing 12-Months

Asset Growth

88.42%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Viridian Therapeutics

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

Viridian Therapeutics (1S1) Earnings & Revenues

Historic Earnings Reports

1S1 Stock 12 Month Forecast

Average Price Target

€30.44

▲(47.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","37":"€37","16.75":"€16.75","23.5":"€23.5","30.25":"€30.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36.58757508,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€36.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.440069240000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€30.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.63235736,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€19.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,16.75,23.5,30.25,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.2,19.614428852307693,21.028857704615383,22.443286556923077,23.85771540923077,25.27214426153846,26.686573113846155,28.101001966153845,29.51543081846154,30.929859670769233,32.344288523076926,33.75871737538462,35.173146227692314,{"y":36.58757508,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.2,19.141543787692306,20.083087575384614,21.024631363076924,21.96617515076923,22.90771893846154,23.849262726153846,24.790806513846157,25.732350301538464,26.67389408923077,27.615437876923078,28.556981664615385,29.498525452307696,{"y":30.440069240000003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.2,18.310181335384616,18.42036267076923,18.530544006153846,18.64072534153846,18.750906676923076,18.861088012307693,18.971269347692306,19.081450683076923,19.19163201846154,19.301813353846153,19.41199468923077,19.522176024615383,{"y":19.63235736,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.995,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.47,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.485,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.2,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >